Scailyte Announces a Collaboration with Turnstone Biologics

Turnstone Biologics, a clinical-stage biotechnology company, is developing new medicines to treat solid tumors by pioneering a differentiated approach with tumor-infiltrating lymphocyte (TIL) therapy, a clinically validated technology. Turnstone’s innovative TIL therapy, which is designed to extend the efficacy of TILs to multiple solid tumor indications by selecting and manufacturing the most potent tumor-reactive T-cells (Selected TILs) for tumor eradication, represents the foundational therapeutic modality driving the Company’s cancer immunotherapy pipeline. The Company’s lead Selected TIL therapy candidate, TIDAL-01, is currently being evaluated in two Phase 1b studies in patients with multiple solid tumor indications. Turnstone is also advancing additional strategies to further potentiate the clinical benefit of Selected TILs, including use in combination with the Company’s novel viral immunotherapy.